Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to determine the safety of Atrovent Nasal Spray 0.06% in pediatric patients (ages 2-5
years) with symptoms of rhinorrhea associated with a naturally occurring common cold or from
symptoms of rhinorrhea associated with allergies